[go: up one dir, main page]

TN2011000366A1 - Use of deferiprone for treatment and prevention of iron-related eye dosorders - Google Patents

Use of deferiprone for treatment and prevention of iron-related eye dosorders

Info

Publication number
TN2011000366A1
TN2011000366A1 TN2011000366A TN2011000366A TN2011000366A1 TN 2011000366 A1 TN2011000366 A1 TN 2011000366A1 TN 2011000366 A TN2011000366 A TN 2011000366A TN 2011000366 A TN2011000366 A TN 2011000366A TN 2011000366 A1 TN2011000366 A1 TN 2011000366A1
Authority
TN
Tunisia
Prior art keywords
iron
deferiprone
eye
treatment
prevention
Prior art date
Application number
TN2011000366A
Other languages
English (en)
Inventor
Michael Spino
Joshua Lawrence Dunaief
Original Assignee
Joshua Lawrence Dunaief
Michael Spino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joshua Lawrence Dunaief, Michael Spino filed Critical Joshua Lawrence Dunaief
Publication of TN2011000366A1 publication Critical patent/TN2011000366A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TN2011000366A 2009-01-26 2011-07-26 Use of deferiprone for treatment and prevention of iron-related eye dosorders TN2011000366A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26
PCT/CA2009/001639 WO2010083582A1 (fr) 2009-01-26 2009-11-12 Utilisation de défériprone pour le traitement et la prévention de troubles oculaires liés au fer

Publications (1)

Publication Number Publication Date
TN2011000366A1 true TN2011000366A1 (en) 2013-03-27

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000366A TN2011000366A1 (en) 2009-01-26 2011-07-26 Use of deferiprone for treatment and prevention of iron-related eye dosorders

Country Status (24)

Country Link
US (1) US20130023569A1 (fr)
EP (1) EP2389179A4 (fr)
JP (1) JP5604631B2 (fr)
KR (1) KR20120078667A (fr)
CN (1) CN102348456A (fr)
AP (1) AP2011005843A0 (fr)
AU (1) AU2009338093B2 (fr)
BR (1) BRPI0920492A2 (fr)
CA (1) CA2750599A1 (fr)
CL (1) CL2011001812A1 (fr)
CR (1) CR20110456A (fr)
EA (1) EA201170970A1 (fr)
IL (1) IL214291A (fr)
MA (1) MA33090B1 (fr)
MX (1) MX2011007947A (fr)
MY (1) MY161269A (fr)
NI (1) NI201100148A (fr)
NZ (1) NZ594728A (fr)
PE (1) PE20120515A1 (fr)
SG (1) SG173145A1 (fr)
TN (1) TN2011000366A1 (fr)
UA (1) UA103366C2 (fr)
WO (1) WO2010083582A1 (fr)
ZA (1) ZA201105514B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242723B1 (fr) 2015-01-09 2021-10-06 The Board of Trustees of the University of Illinois Utilisation du hinokitiol pour la restauration de la physiologie dans des organismes présentant une carence en fer
CA3172668A1 (fr) 2017-10-25 2019-05-02 Chiesi Farmaceutici S.P.A. Comprimes de deferiprone a liberation retardee et procedes d'utilisation correspondants
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
JP4757024B2 (ja) * 2002-11-07 2011-08-24 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
WO2004071425A2 (fr) * 2003-02-06 2004-08-26 Bioresponse, Llc Utilisation combinee d'indoles cruciferes et de chelateurs pour le traitement d'etats lies au papillomavirus
US20070197649A1 (en) * 2006-02-22 2007-08-23 Arnold Munnich Use of deferiprone and methods to treat and/or prevent Friedreich Ataxia resulting from intracellular mishandling of iron
CN101987849B (zh) 2006-04-14 2013-05-08 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性(amd)的方法
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
IL214291A0 (en) 2011-09-27
EP2389179A4 (fr) 2012-08-29
NI201100148A (es) 2012-03-06
US20130023569A1 (en) 2013-01-24
CR20110456A (es) 2012-05-31
IL214291A (en) 2015-03-31
CL2011001812A1 (es) 2012-02-03
MY161269A (en) 2017-04-14
CN102348456A (zh) 2012-02-08
EP2389179A1 (fr) 2011-11-30
AU2009338093B2 (en) 2014-08-28
MA33090B1 (fr) 2012-03-01
CA2750599A1 (fr) 2010-07-29
UA103366C2 (ru) 2013-10-10
NZ594728A (en) 2013-03-28
JP5604631B2 (ja) 2014-10-08
AU2009338093A1 (en) 2011-09-08
SG173145A1 (en) 2011-08-29
KR20120078667A (ko) 2012-07-10
BRPI0920492A2 (pt) 2019-07-09
EA201170970A1 (ru) 2012-03-30
PE20120515A1 (es) 2012-05-20
WO2010083582A1 (fr) 2010-07-29
ZA201105514B (en) 2012-10-31
MX2011007947A (es) 2011-12-14
AP2011005843A0 (en) 2011-08-31
JP2012515725A (ja) 2012-07-12

Similar Documents

Publication Publication Date Title
WO2011113013A3 (fr) Procédés et compositions pour le traitement d'états viraux ou induits par des virus
WO2012050831A3 (fr) Traitement combiné d'affections dermatologiques
BR112015012312A2 (pt) método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2011099832A3 (fr) Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2013180834A3 (fr) Compositions et procédés d'inhibition de masp-1 et/ou masp-3 pour le traitement l'hémoglobinurie paroxysmique nocturne
WO2011085162A3 (fr) Compositions topiques transdermiques de dexmédétomidine et leurs procédés d'utilisation
WO2010132882A8 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
WO2006098603A3 (fr) Composition renfermant de l'isoorientine pour suppression d'histamine
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
WO2012047645A3 (fr) Traitement d'association pour l'acné rosacée
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
WO2009109654A8 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
WO2014153385A3 (fr) Méthodes de traitement de troubles métaboliques
MX339829B (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
WO2014071168A3 (fr) Administration d'inhibiteurs de la signalisation tgfbêta, dérivés de benzothiazépine ou combinaisons de ceux-ci pour améliorer la fonction musculaire chez des patients cancéreux
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
WO2013096335A8 (fr) Administration d'un antagoniste de l'intégrine alpha-5-bêta 1 afin de lutter contre l'angiogenèse et de traiter le cancer
CA2866819C (fr) Procede de traitement de l'inflammation
WO2015061777A3 (fr) Traitement de l'urticaire chronique idiopathique, de l'anaphylaxie et de l'œdème de quincke